logo

[breadcrumb_custom]

CYTH’s Stock Market Adventure: -8.18% YTD Growth Amidst Volatility

Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The metric has seen a significant loss of -8.18% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 2.82%. Over the past 30 days, the price of CYTH has leaped by -9.32%. And in the last five days, it has surged by 2.10%.

Cyclo Therapeutics Inc saw a rather consistency, in terms of market performance. The company’s stock reached its highest point at $2.57 on 06/13/23, while the lowest price for the same duration was marked at $0.67 on 04/05/23.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

52-week price history of CYTH Stock

Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Cyclo Therapeutics Inc’s current trading price is -43.19% away from its 52-week high, while its distance from the 52-week low is 117.91%. The stock’s price range during this time has been between $0.67 and $2.57. The trading volume for the Healthcare sector company’s shares reached about 1.09 million for the day, which was higher than the average daily volume of 0.1 million over the last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Cyclo Therapeutics Inc (CYTH) has experienced a quarterly decline of -8.18% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 41.93M and boasts a workforce of 8 employees.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 1.5650, with a change in price of +0.4100. Similarly, Cyclo Therapeutics Inc recorded 116,256 in trading volume during the last 100 days, posting a change of +39.05%.

CYTH’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CYTH stands at 0.22. Similarly, the long-term debt-to-equity ratio is also 0.00.

CYTH Stock Stochastic Average

Today, Cyclo Therapeutics Inc’s raw stochastic average for the past 50 days stands at 23.39%, indicating a decline from the raw stochastic average of the last 20 days, which was 37.74%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 18.85% and 10.76% respectively.

On Key

Related Posts